Breast cancer brain metastases genomic profiling identifies alterations targetable by immune-checkpoint and PARP inhibitors
- Location
-
Deutsche Nationalbibliothek Frankfurt am Main
- Extent
-
1 Online-Ressource.
- Language
-
Englisch
- Bibliographic citation
-
Breast cancer brain metastases genomic profiling identifies alterations targetable by immune-checkpoint and PARP inhibitors ; volume:8 ; number:1 ; day:20 ; month:12 ; year:2024 ; pages:1-11 ; date:12.2024
npj precision oncology ; 8, Heft 1 (20.12.2024), 1-11, 12.2024
- Creator
-
Giannoudis, A.
Sokol, E. S.
Bhogal, T.
Ramkissoon, S. H.
Razis, E. D.
Bartsch, R.
Shaw, J. A.
McGregor, K.
Clark, Alison
Huang, R.S.P
Palmieri, C.
- Contributor
-
SpringerLink (Online service)
- DOI
-
10.1038/s41698-024-00761-0
- URN
-
urn:nbn:de:101:1-2503012100167.201624981848
- Rights
-
Open Access; Der Zugriff auf das Objekt ist unbeschränkt möglich.
- Last update
-
15.08.2025, 7:30 AM CEST
Data provider
This object is provided by:
Deutsche Nationalbibliothek. If you have any questions about the object, please contact the data provider.
Deutsche Nationalbibliothek. If you have any questions about the object, please contact the data provider.
Associated
- Giannoudis, A.
- Sokol, E. S.
- Bhogal, T.
- Ramkissoon, S. H.
- Razis, E. D.
- Bartsch, R.
- Shaw, J. A.
- McGregor, K.
- Clark, Alison
- Huang, R.S.P
- Palmieri, C.
- SpringerLink (Online service)
Other Objects (12)
Cell cycle checkpoint in cancer: a therapeutically targetable double-edged sword
Molecular and functional profiling identifies therapeutically targetable vulnerabilities in plasmablastic lymphoma
Molecular and functional profiling identifies therapeutically targetable vulnerabilities in plasmablastic lymphoma
Prospects for combining immune checkpoint blockade with PARP inhibition
Systematic analysis of RNA-binding proteins identifies targetable therapeutic vulnerabilities in osteosarcoma
Application of PARP inhibitors combined with immune checkpoint inhibitors in ovarian cancer
Prediction of homologous recombination deficiency identifies colorectal tumors sensitive to PARP inhibition
Targetable NOTCH1 rearrangements in reninoma
PARP inhibitors
Super-enhancer profiling identifies novel critical and targetable cancer survival gene LYL1 in pediatric acute myeloid leukemia
Glycoproteomics identifies HOMER3 as a potentially targetable biomarker triggered by hypoxia and glucose deprivation in bladder cancer
Understanding tumour growth variability in breast cancer xenograft models identifies PARP inhibition resistance biomarkers
Cell cycle checkpoint in cancer: a therapeutically targetable double-edged sword
Molecular and functional profiling identifies therapeutically targetable vulnerabilities in plasmablastic lymphoma
Molecular and functional profiling identifies therapeutically targetable vulnerabilities in plasmablastic lymphoma
Prospects for combining immune checkpoint blockade with PARP inhibition
Systematic analysis of RNA-binding proteins identifies targetable therapeutic vulnerabilities in osteosarcoma
Application of PARP inhibitors combined with immune checkpoint inhibitors in ovarian cancer
Prediction of homologous recombination deficiency identifies colorectal tumors sensitive to PARP inhibition
Targetable NOTCH1 rearrangements in reninoma
PARP inhibitors
Super-enhancer profiling identifies novel critical and targetable cancer survival gene LYL1 in pediatric acute myeloid leukemia
Glycoproteomics identifies HOMER3 as a potentially targetable biomarker triggered by hypoxia and glucose deprivation in bladder cancer
Understanding tumour growth variability in breast cancer xenograft models identifies PARP inhibition resistance biomarkers
Cell cycle checkpoint in cancer: a therapeutically targetable double-edged sword
Molecular and functional profiling identifies therapeutically targetable vulnerabilities in plasmablastic lymphoma
Molecular and functional profiling identifies therapeutically targetable vulnerabilities in plasmablastic lymphoma
Prospects for combining immune checkpoint blockade with PARP inhibition
Systematic analysis of RNA-binding proteins identifies targetable therapeutic vulnerabilities in osteosarcoma
Application of PARP inhibitors combined with immune checkpoint inhibitors in ovarian cancer
Prediction of homologous recombination deficiency identifies colorectal tumors sensitive to PARP inhibition
Targetable NOTCH1 rearrangements in reninoma
PARP inhibitors
Super-enhancer profiling identifies novel critical and targetable cancer survival gene LYL1 in pediatric acute myeloid leukemia
Glycoproteomics identifies HOMER3 as a potentially targetable biomarker triggered by hypoxia and glucose deprivation in bladder cancer